AUPH - Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.

52W High

$12.82

52W Low

$6.42

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.27

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

28.84

Forward P/E (<15 better)

18.94

EV/EBITDA (<8 favorable)

16.17

EV/Revenue (<3 favorable)

5.38

P/S (TTM) (<3 favorable)

6.28

P/B (<3 favorable)

4.87

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

7.15%

Institutions (25–75% balanced)

45.56%

Shares Outstanding

131,630,000

Float

128,061,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

260,111,000

Gross Profit (TTM)

208,506,000

EPS (TTM)

0.43

Profit Margin (>10% good)

0.23%

Operating Margin (TTM) (higher better)

0.29%

ROE (TTM) (>15% strong)

0.17%

EPS YoY (Quarterly) (>10% good)

30.67

Revenue YoY (Quarterly) (>8% good)

0.22

Momentum

Bearish momentum

Value

0.5316

0.5063

Trend

Rising

Signal Cross

No cross

As of

Sep. 11, 2025